Cargando…
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Alzheimer’s disease (AD) is the most common dementia in the industrialized world, with prevalence rates well over 30% in the over 80-years-old population. The dementia causes enormous costs to the social healthcare systems, as well as personal tragedies for the patients, families and caregivers. AD...
Autores principales: | Moreth, Jens, Mavoungou, Chrystelle, Schindowski, Katharina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681567/ https://www.ncbi.nlm.nih.gov/pubmed/23663286 http://dx.doi.org/10.1186/1742-4933-10-18 |
Ejemplares similares
-
Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
por: Moreth, Jens, et al.
Publicado: (2013) -
Data of rational process optimization for the production of a full IgG and its Fab fragment from hybridoma cells
por: Röhm, Martina, et al.
Publicado: (2016) -
Protein aerosol for intranasal nose to brain (N2B) delivery
por: Stützle, Martina, et al.
Publicado: (2015) -
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
por: Nuvolone, Mario, et al.
Publicado: (2022) -
What are the most promising medicines?
por: Vaughan, Adam
Publicado: (2020)